Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) - Net Assets
Based on the latest financial reports, Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) has net assets worth CN¥7.74 Billion CNY (≈ $1.13 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.59 Billion ≈ $1.26 Billion USD) and total liabilities (CN¥842.81 Million ≈ $123.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688578 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.74 Billion |
| % of Total Assets | 90.18% |
| Annual Growth Rate | 57.45% |
| 5-Year Change | 384.43% |
| 10-Year Change | N/A |
| Growth Volatility | 509.67 |
Shanghai Allist Pharmaceuticals Co. Ltd. A - Net Assets Trend (2017–2025)
This chart illustrates how Shanghai Allist Pharmaceuticals Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See 688578 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Shanghai Allist Pharmaceuticals Co. Ltd. A (2017–2025)
The table below shows the annual net assets of Shanghai Allist Pharmaceuticals Co. Ltd. A from 2017 to 2025. For live valuation and market cap data, see 688578 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥14.40 Billion ≈ $2.11 Billion |
+172.65% |
| 2024-12-31 | CN¥5.28 Billion ≈ $773.04 Million |
+32.66% |
| 2023-12-31 | CN¥3.98 Billion ≈ $582.73 Million |
+24.95% |
| 2022-12-31 | CN¥3.19 Billion ≈ $466.37 Million |
+7.19% |
| 2021-12-31 | CN¥2.97 Billion ≈ $435.08 Million |
+3.31% |
| 2020-12-31 | CN¥2.88 Billion ≈ $421.15 Million |
+143.00% |
| 2019-12-31 | CN¥1.18 Billion ≈ $173.31 Million |
+1567.31% |
| 2018-12-31 | CN¥71.04 Million ≈ $10.39 Million |
-81.37% |
| 2017-12-31 | CN¥381.26 Million ≈ $55.79 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Allist Pharmaceuticals Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 881.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.01 Billion | 46.25% |
| Other Comprehensive Income | CN¥6.50 Billion | 100.00% |
| Total Equity | CN¥6.50 Billion | 100.00% |
Shanghai Allist Pharmaceuticals Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Allist Pharmaceuticals Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hancock Whitney Corp
NASDAQ:HWC
|
$5.60 Billion |
|
IMCD NV
AS:IMCD
|
$5.60 Billion |
|
Thai Airways International Public Company Limited
BK:THAI
|
$5.60 Billion |
|
Enel Chile SA ADR
NYSE:ENIC
|
$5.60 Billion |
|
Yancoal Australia Ltd
AU:YAL
|
$5.60 Billion |
|
GXO Logistics Inc
NYSE:GXO
|
$5.60 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
$5.59 Billion |
|
Tsingtao Brewery Co Ltd
SHG:600600
|
$5.59 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Allist Pharmaceuticals Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,282,813,244 to 6,498,806,000, a change of 1,215,992,756 (23.0%).
- Net income of 2,181,293,000 contributed positively to equity growth.
- Dividend payments of 360,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 6,498,806,000.
- Other factors decreased equity by 7,104,106,244.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥2.18 Billion | +33.56% |
| Dividends Paid | CN¥360.00 Million | -5.54% |
| Other Comprehensive Income | CN¥6.50 Billion | +100.0% |
| Other Changes | CN¥-7.10 Billion | -109.31% |
| Total Change | CN¥- | 23.02% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Allist Pharmaceuticals Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 80.56x to 5.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.06 | CN¥85.00 | x |
| 2018-12-31 | CN¥0.20 | CN¥85.00 | x |
| 2019-12-31 | CN¥3.28 | CN¥85.00 | x |
| 2020-12-31 | CN¥7.79 | CN¥85.00 | x |
| 2021-12-31 | CN¥6.51 | CN¥85.00 | x |
| 2022-12-31 | CN¥7.08 | CN¥85.00 | x |
| 2023-12-31 | CN¥8.84 | CN¥85.00 | x |
| 2024-12-31 | CN¥11.75 | CN¥85.00 | x |
| 2025-12-31 | CN¥14.45 | CN¥85.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Allist Pharmaceuticals Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 33.56%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 42.18%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.22x
- Recent ROE (33.56%) is above the historical average (-12.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -10.21% | -503.87% | 0.02x | 1.33x | CN¥-77.06 Million |
| 2018 | -137.10% | -2108.11% | 0.01x | 5.28x | CN¥-104.50 Million |
| 2019 | -33.56% | -63123.39% | 0.00x | 1.12x | CN¥-515.94 Million |
| 2020 | -10.79% | -55361.45% | 0.00x | 1.04x | CN¥-598.32 Million |
| 2021 | 0.61% | 3.45% | 0.17x | 1.05x | CN¥-279.05 Million |
| 2022 | 4.10% | 16.50% | 0.23x | 1.08x | CN¥-188.18 Million |
| 2023 | 16.18% | 31.92% | 0.46x | 1.10x | CN¥245.95 Million |
| 2024 | 27.07% | 40.19% | 0.60x | 1.12x | CN¥901.57 Million |
| 2025 | 33.56% | 42.18% | 0.65x | 1.22x | CN¥1.53 Billion |
Industry Comparison
This section compares Shanghai Allist Pharmaceuticals Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Allist Pharmaceuticals Co. Ltd. A (688578) | CN¥7.74 Billion | -10.21% | 0.11x | $5.60 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Shanghai Allist Pharmaceuticals Co. Ltd. A
Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl c… Read more